2 completed, 1 terminated. 2 Phase 1, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Edward Kim: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | Terminated | Edward Kim | 8 | 2018-10-16 | 2026-07-29 |
| Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy Carbon C 14 Oxaliplatin, Oxaliplatin - Colon Adenocarcinoma | Not applicable | Completed | Edward Kim | 6 | 2015-10-16 | 2021-03-30 |
| Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer alisertib, gemcitabine - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 1 | Completed | Edward Kim | 26 | 2013-08-09 | 2022-08-02 |
Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Pancreatic Neoplasms (1)
Gemcitabine (1) · MLN 8237 (1) · Nivolumab (1) · Oxaliplatin (1) · linrodostat (1)
United States (3)
Karen Kelly (1)
P30CA093373 (3)